Breaking p53 aggregations similar with prion-like behavior could be the novel therapeutic target in the anti-cancer therapy, as well as other PMDs from protein aggregations, such as Alzheimer disease and Parkinson disease.[43–48]. This evidence concerns the gene TP53 and cancer.